Citation Information :
Tulek N, Ozsoy M, Moroglu C, Cagla Sonmezer M, Temocin F, Tuncer Ertem G, Sebnem Erdinc F. Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey. Euroasian J Hepatogastroenterol 2015; 5 (2):95-97.
Background: Hepatitis A virus (HAV) can cause significant pathology in patients with chronic hepatitis
B virus (HBV), however, HAV can be prevented by vaccination. The aim of this study was to determine
the implication of vaccination against HAV vaccine in patients with chronic hepatitis B.
Materials and methods: The seroprevalence of anti-HAV IgG antibodies was investigated in the patients
with chronic hepatitis B. Anti-HAV IgG antibodies were detected by commercially available ELISA kit.
Results: A total of 673 patients (354 males, 319 females with age range of 17–78 years) with chronic
hepatitis B were included the study. Hepatitis A virus seropositivity rate was 34% in the patients younger
than 20 years, 79% in the age group of 20 to 29 years, and 100% after 35 years of age.
Discussion: Hepatitis A virus vaccination may be recommended for young adult patients with chronic
hepatitis B in Turkey.
Averhoff F, Khudyakov Y, Bell BP. Hepatitis A Virus. In: Bennetth JE, Dolin R, Blaser M, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Saunders, Elsevier; 2015. p. 2096-2110
Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis 2011 Dec 12;11:337
The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. Geneva: World Health Organization; 2010. WHO/IVB/10.0
Changing epidemiology of hepatitis A infection in Izmir, Turkey. Vaccine 2011;29(37):6259-6261
Hepatitis A seroprevalence in children and adolescents aged 1 to 18 years among a low socioeconomic population in Izmir, Turkey. Travel Med Infect Dis 2012;10(1):43-47. Graph 1: Anti-HAV IgG seroprevalence rate among the patients with chronic hepatitis B Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey Euroasian Journal of Hepato-Gastroenterology, July-December 2015;5(2):95-97 97 EJOHG 6. Uysal G, Tülek N, Güven MA.Çocukluk çağı viral hepatitlerde etyolojik ajanların dağılımı. Flora 1998;3:274-275
Turkish national study team. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr 2002;44(3):204-210
Hepatitis A seroprevalence and demographics in Turkish children in Ankara. Pediatr Int 2009;51(1):5-8
Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatol 2003;38(3):613-618
Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection 2005;(3): 136-139
Factors influencing the severity of acute viral hepatitis A. Korean J Hepatol 2010;16(3):295-300
Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Database Syst Rev 2012;7:CD009051
Available at: http://www.cdc.gov/vaccines/ schedules/hcp/imz/child-adolescent.html1., accessed 05 April 2015
Available at: http://www. cdc.gov/vaccines/schedules/hcp/adult.html, accessed 05 April 2015.
